• Do you need definitive Huntington’s Disease market data?
• Succinct Huntington’s Disease market analysis?
• Technological insight?
• Actionable business recommendations?
Read on to discover how this definitive report can transform your own research and save you time.
The Global Huntington’s Disease market shows immense potential to grow in the future, growing in line with some emerging trends. One such trend is the increasing strategic partnerships in a move to introduce or diversify product portfolios pertaining to drugs. Another trend is advances in biomedical sciences and introduction of nanotechnologies in the global pharmaceutical market, which are revolutionising the development of medicines.
Lastly, the study of the pathogenesis of disease at genetic and molecular level have led to the discovery of new targets for therapy and producing disease modifying drugs.
Report highlights
• 77 quantitative tables, charts, and graphs across 163 pages
• Global Huntington’s Disease market outlook and analysis from 2018-2028
• Global Huntington’s Disease submarket forecasts and analysis from 2018-2028
• Antidopaminergics
• Antipsychotics
• Anticonvulsants
• Antidepressants
• Other
• Regional and National Huntington’s Disease market forecasts 2018-2028
• North America forecast 2018-2028
• US forecast 2018-2028
• Rest of North America forecast 2018-2028
• Europe forecast 2018-2028
• Germany forecast 2018-2028
• UK forecast 2018-2028
• France forecast 2018-2028
• Italy forecast 2018-2028
• Spain forecast 2018-2028
• Rest of Europe forecast 2018-2028
• Rest of World forecast 2018-2028
Key questions answered
• What does the future hold for the Pharmaceutical industry with regards to Huntington’s Disease
• Where should you target your business strategy?
• Which applications should you focus upon?
• Which disruptive technologies should you invest in?
• Which companies should you form strategic alliances with?
• Which company is likely to success and why?
• What business models should you adopt?
• What industry trends should you be aware of?
Target audience
• Leading Pharmaceutical companies
• Suppliers
• Contractors
• Technologists
• R&D staff
• Consultants
• Analysts
• CEO’s
• CIO’s
• COO’s
• Business development managers
• Investors
• Governments
• Agencies
• Banks
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Why You Should Read This Report
1.2 How This Report Delivers
1.3 Key Questions Answered by This Analytical Report Include:
1.4 Who is This Report For?
1.5 Methodology
1.5.1 Primary Research
1.5.2 Secondary Research
1.5.3 Market Evaluation & Forecasting Methodology
1.6 Frequently Asked Questions (FAQ)
1.7 Associated Visiongain Reports
1.8 About Visiongain
2. Introduction to Huntington’s Disease
2.1 What Are the Causes And Risk Factors Of Huntington’s Disease?
2.1.1 Risk Factors
2.1.1.1 Alcohol Intake
2.1.1.2 Pneumonia:
2.1.1.3 Stress
2.2 Symptoms of Huntington’s Disease
2.2.1 Symptoms in Adult Onset
2.2.2 Movement Disorders
2.2.3 Cognitive Disorders
2.2.4 Psychiatric Disorders
2.2.5 Symptoms in Juvenile Onset
2.2.6 Behavioural Changes:
2.3 Diagnosis of Huntington’s Disease
2.3.1 Neurological Tests:
2.3.2 Brain Function and Imaging Tests:
2.3.3 Genetic Testing:
2.3.4 Psychiatric Tests:
2.3.5 Test in Pregnancy:
2.3.6 Preimplantation Genetic Diagnosis:
2.4 Treatment of Huntington’s Disease
2.4.1 Medications for Movement Disorders:
2.4.2 Medications for Psychiatric Disorders:
2.4.3 Psychotherapy
2.4.4 Speech Therapy
2.4.5 Physical Therapy
2.4.6 Occupational Therapy
2.5 Epidemiology of Huntington’s Disease
2.6 Social and Economic Burden
2.6.1 Mortality
2.6.2 Morbidity
2.6.3 Economic Impact
2.7 Introduction to the Global Huntington’s Disease Market
3. Global Huntington’s Disease Market Size And Forecast By Drug Class
3.1 Market Segmentation by Application
3.2 Global Antidopaminergics Market
3.2.1 Market Overview
3.2.2 Market Size and Forecast
3.3 Global Antipsychotics Market
3.3.1 Market Overview
3.3.2 Market Size and Forecast
3.4 Global Anticonvulsants Market
3.4.1 Market Overview
3.4.2 Market Size and Forecast
3.5 Global Antidepressants Market
3.5.1 Market Overview
3.5.2 Market Size and Forecast
3.6 Global Other Huntington’s Disease Drugs Market
3.6.1 Market Overview
3.6.2 Market Size and Forecast
4. Leading Drugs in Global Huntington’s Disease Market, 2017
4.1 Xenazine (tetrabenazine)
4.2 Austedo (Deutetrabenazine)
4.3 Clozapine
4.4 Haloperidol
4.5 Abilify
4.6 Risperdal
5. Leading National Markets Forecast 2017-2028
5.1 Geographical Breakdown of Global Huntington’s Disease Drugs Market, 2016
5.2 Huntington’s Disease Drugs Market in the Americas, 2016
5.3 Huntington’s Disease Drugs Market in the EU5, 2016
5.3.1 Market Forecast of the EU5 Countries, 2017-2028
5.3.2 The UK
5.3.3 Germany
5.3.4 France
5.3.5 Spain
5.3.6 Italy
5.3.7 Huntington’s Disease Drugs Market in the Rest of Europe, 2016
5.4 Huntington’s Disease Drugs Market in the Rest of the World, 2016
5.4.1 Japan
5.4.2 China
5.4.3 Russia
6. Qualitative Analysis of the Huntington’s Disease Market
6.1 Market Growth Drivers
6.1.1 Unmet Medical Need
6.1.2 Special Regulatory Provisions for Rare Diseases
6.1.3 Designated ICD-10 Code
6.1.4 Increased investment in R&D
6.1.5 Alternative Therapies
6.2 Market Challenges
6.2.1 Poor Diagnosis Rates
6.2.2 Limited Patient Population
6.2.3 Stringent Regulatory Guidelines
6.2.4 Alternative programs for management of mental disorders
6.3 Market Trends
6.3.1 Advances in Biomedical Sciences
6.3.2 Focus on Regenerative Therapies for Mental Disorders
6.3.3 Rising Public Interest Toward Mental Health
6.3.4 Novel Mechanisms Targeted by Pipeline Candidates
6.3.5 Emergence of First-in-class Pipeline Molecules
7. Pipeline Molecules
7.1 Promising Potential Pipeline Molecules
7.1.1 Phase III Molecules
7.1.1.1 Tetrabenazine (Xenazine)
7.1.1.2 Deutetrabenazine (Austedo)
7.1.1.3 PRIDOPIDINE
7.1.2 Phase II Molecules
7.1.2.1 Laquinimod
7.1.2.2 PBT2
7.1.2.3 VX15 (SIGNAL)
7.1.2.4 PDE10A Inhibitor
7.1.2.5 Deep Brain Stimulation (DBS)
7.1.2.6 Cysteamine (RP103)
7.1.3 Phase I Molecules
7.1.3.1 Antisense Oligonucleotide Huntingtin Lowering Drug
7.1.4 Phase Pre-Clinical R&D
7.1.4.1 Pre- Cell/HD Cell
7.1.4.2 AAV-SHRNA
7.1.4.3 Zinc Finger DNA-Binding Protein (ZFP)
7.1.4.4 HDAC Inhibitor
7.1.4.5 KMO Inhibitor
8. Leading Companies in Global Huntington’s Disease Market, 2017
8.1 Hoffmann-La Roche Ltd.
8.1.1 SWOT Analysis:
8.2 H. Lundbeck
8.2.1 Business Strategy:
8.2.2 SWOT Analysis:
8.3 Teva Pharmaceutical Industries Ltd.
8.3.1 Business Strategy:
8.3.2 SWOT Analysis:
8.4 Prana Biotechnology
8.5 Sangamo Therapeutics Inc.
8.6 Horizon Pharma Plc.
8.6.1 Revenue from Business Units:
8.6.2 Business Strategy:
8.6.2.1 Key Developments:
8.6.2.2 SWOT Analysis:
8.7 Omeros Corp.
8.7.1 SWOT Analysis:
8.8 Valeant Pharmaceuticals International Inc.
8.8.1 Business strategy:
8.8.2 SWOT Analysis
9. Executive Summary and Recommendations
10. Glossary
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
List of Figures
Figure 1.1 Example of Huntington's Disease Market by Regional Market Share Forecast 2017, 2022, 2027(% Share)
Figure 2.1 Example of Huntington's Disease Market by Regional Market Share Forecast 2017, 2022, 2027(% Share)
Figure 2.2 Global Huntington's Disease Market Segmentation by Drug Class (% Share)
Figure 3.1 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
Figure 3.2 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
Figure 3.3 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
Figure 3.4 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
Figure 3.5 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
Figure 3.6 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
Figure 5.1 Global Huntington's Disease Drugs Market Segmentation by Region/Country
Figure 5.2 Global Huntington's Disease Drugs Market by Region: Revenue ($m)
Figure 5.3 Global Huntington's Disease Drugs Market by Region: Market Share 2016 (%)
Figure 5.4 Global Huntington's Disease Drugs Market by Region: AGR 2017-2028 (%)
Figure 5.5 Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2017-2028 (%)
Figure 5.6 Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2017 (%)
Figure 5.7 Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2022 (%)
Figure 5.8 Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2027 (%)
Figure 5.9 Huntington's Disease Drugs Market in the US: 2016 Market Share %
Figure 5.10 Huntington's Disease Drugs Market in the US: 2016 Revenue ($m), Market Share %
Figure 5.11 Huntington's Disease Market Forecast in the US 2017-2028: Revenue ($m), AGR (%)
Figure 5.12 Huntington's Disease Drugs Market in the EU5 2016: Global Market Share (%)
Figure 5.13 Huntington's Disease Drugs Market in the EU5 Countries 2016: Market Share (%)
Figure 5.14 Huntington's Disease Drugs Market in the EU5 Countries 2028 Market Share (%)
Figure 5.15 Huntington's Disease Drugs Market Forecast in EU5: Revenue ($m), AGR (%),2017-2028
Figure 5.16 Global Huntington's Disease Drugs Market Forecast in The UK 2017-2028: Revenue ($m), AGR (%)
Figure 5.17 Global Huntington's Disease Drugs Market Forecast in Germany 2017-2028: Revenue ($m), AGR (%)
Figure 5.18 Global Huntington's Disease Drugs Market Forecast in France 2017-2028: Revenue ($m), AGR (%)
Figure 5.19 Global Huntington's Disease Drugs Market Forecast in Spain 2017-2028: Revenue ($m), AGR (%)
Figure 5.20 Global Huntington's Disease Drugs Market Forecast in Italy 2017-2028: Revenue ($m), AGR (%)
Figure 5.21 Huntington's Disease Drugs Market Forecast in the RoE: Revenue ($m), AGR (%),2017-2028
Figure 5.22 Huntington's Disease Drugs Market Forecast in RoW: Revenue ($m), AGR (%),2017-2028
Figure 8.1: Roche: Sales 2016
Figure 8.2: Roche: Sales 2016
Figure 8.3: H. Lundbeck: SWOT Analysis 2016
Figure 8.4 Teva: SWOT Analysis 2016
Figure 8.5 Horizon Revenue by Business Unit
Figure 8.6 Horizon: Drugs under Orphan Business Unit:
Figure 8.7 Horizon Drugs under Primary Care Unit:
Figure 8.8 Horizon: Drugs under Rheumatology Business Unit:
Figure 8.9 Horizon SWOT Analysis
Figure 8.10 Omeros Corp: SWOT Analysis
Figure 8.11 Valeant SWOT Analysis
Figure 9.1 Global Huntington's Disease Market Forecast 2017-2028: Revenue ($m), AGR (%)
List of Tables
Table 1.1 Example of Huntington's Disease Market by Regional Market Forecast 2017-2028 (US$m, AGR %, Cumulative)
Table 2.1: Prevalence of Huntington's Disease by Geography 2015
Table 2.2: Incidence of Huntington's Disease by Geography 2015
Table 3.1 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 3.2 Global Antidopaminergics Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 3.3 Global Antipsychotics Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 3.4 Global Anticonvulsants Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 3.5 Global Antidepressants Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 3.6 Global Antidepressants Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 5.1 Global Huntington's Disease Drugs Market by Region: Revenue ($m), and Market Share (%), 2016
Table 5.2 Global Huntington's Disease Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%),2017-2028
Table 5.3 Global Huntington's Disease Drugs Market by Region: AGR 2017-2028 (%)
Table 5.4 Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2017-2028 (%)
Table 5.7 Global Huntington's Disease Drugs Market Forecast in the Americas: Revenue ($m), AGR (%), CAGR (%),2017-2028
Table 5.8 Global Huntington's Disease Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%),2017-2028
Table 5.9 Huntington's Disease Drugs Market in the EU5, 2017
Table 5.10 Huntington's Disease Drugs Market Forecast in EU5: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.11 Huntington's Disease Drugs Market Forecast in UK: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.12 Huntington's Disease Drugs Market Forecast in Germany: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.13 Huntington's Disease Drugs Market Forecast in France: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.14 Huntington's Disease Drugs Market Forecast in Spain: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.15 Huntington's Disease Drugs Market Forecast in Italy: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.16 Huntington's Disease Drugs Market Forecast in RoE: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.17 Huntington's Disease Drugs Market Forecast in Row: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 7.1: Active Pipeline Molecules under Development for Treating Huntington's Disease
Table 7.1: Active Pipeline Molecules under Development for Treating Huntington's Disease (Continued)
Table 8.1:Roche: Overview 2016
Table 8.2: H. Lundbeck: Overview 2016
Table 8.3: Teva: Overview 2016
Table 8.4 Prana: Overview 2016
Table 8.5: Sangamo: Overview 2016
Table 8.6: Horizon: Overview 2016
Table 8.7: Omeros: Overview 2016
Table 8.8: Valeant: Overview 2016
Abbott Laboratories,Inc.,
Actavis
Aldagen
Allergan, Inc
Astra Zeneca
Auspex Pharmaceuticals Inc
Australian Securities Exchange
Bausch + Lomb
Baxter International, Inc.
BioMarin
Boston Scientific Corporation
BrainCells
Bristol-Meyers Squibb
Cardinal Health
Cephalon Inc.
CHDI Foundation
Defined Health
Dow AgroSciences
Eli Lilly
F. Hoffmann-La Roche AG
Fate Therapeutics
Forest Laboratories
Gedeon Richter
Genzyme
Germany Effects
Glaxo SmithKline
H. Lundbeck
Horizon Pharmaceutical LLC.
Hospira, Inc
InterMune
Intra-Cellular Therapies
Ionis Pharmaceuticals
Isis Pharmaceuticals
iZumi Bio.
Janssen Pharmaceuticals
Johnson & Johnson
KDL
Lundbeck Pharmaceuticals
Lupin
Luye Pharma
Marnac
Medtronic, Inc.
Merck Serono
MSI Methylation Sciences
Mylan Pharmaceuticals
Naurex
Neuroptix Corporation
Novartis AG
Omeros Corporation
Opko Health
Otsuka America Pharmaceutical, Inc.
Otsuka Pharmaceutical
Ovation Pharmaceuticals
Pfizer, Inc.
Prana Biotechnology
Raptor Pharmaceuticals
River Vision Development Corp
Sangamo BioSciences, Inc
Sangamo Therapeutics
Sanofi
Shionogi Seiyaku
Shire plc
Sigma-Aldrich Corporation
SK Biopharmaceuticals
Teva Pharmaceutical Industries
Torrent Pharma
UCB Group
Vaccinex Inc.
Vidara Therapeutics International
Voyager Therapeutics Inc
List of Organizations
American Gastroenterological Association (AGA) Institute
Anxiety and Depression Association of America
Brain and Spinal Cord Institute
Centre Hospitalier Universitaire
European Huntington’s Disease Network (EHDN
European Medicines Agency (EMA)
FDA’s Office of Orphan Products Development
FENIN, the Spanish Healthcare Technology Federation
Medicaid
Ministry of Health, Labor and Welfare (MHLW)
Pharmaceutical Research and Manufacturers of America (PhRMA
The Centers for Disease Control and Prevention (CDC)
The Organisation for Economic Co-operation and Development (OECD)
The Scripps Research Institute
UK National Health Service (NHS)
University Clinic Dusseldorf
University of Auckland, New Zealand
University of California at Davis
US Food & Drug Administration (FDA)
World Bank
World Health Organisation (WHO)